Rep. Matsui Introduces Bipartisan Bill to Force Medicare Plans to Cover Cheaper Generic Drugs
This bill was recently introduced in the House and is currently being reviewed by two committees. It is in the early stages of the legislative process and is considered active. There are no upcoming votes scheduled at this time.
The bill has bipartisan support and addresses high drug costs, which is a popular issue. However, it faces potential pushback from insurance companies and brand-name drug makers.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
Small generic drug manufacturers and biosimilar producers could see increased market demand if Medicare Part D plans are required to cover their products in preferred positions. This creates a more level playing field against large brand-name pharmaceutical companies that have used rebate arrangements to maintain formulary dominance.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
No votes or related bills recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.
Analysis generated by AI. Always verify with official sources.